☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
InnoCare Pharma
InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymph...
March 13, 2024
InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies
January 16, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.